1. |
Lyme disease vaccineACIP recommendations |
|
Inpharma Weekly,
Volume &NA;,
Issue 1193,
1999,
Page 2-2
&NA;,
Preview
|
PDF (873KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1999
数据来源: ADIS
|
2. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 1193,
1999,
Page 3-3
&NA;,
Preview
|
PDF (768KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1999
数据来源: ADIS
|
3. |
Donepezil cost saving in Alzheimer's |
|
Inpharma Weekly,
Volume &NA;,
Issue 1193,
1999,
Page 4-4
&NA;,
Preview
|
PDF (760KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1999
数据来源: ADIS
|
4. |
UK debate over interferon-&bgr; prescribing continues |
|
Inpharma Weekly,
Volume &NA;,
Issue 1193,
1999,
Page 5-6
Tracey Wright,
Preview
|
PDF (1646KB)
|
|
摘要:
The licensing of &bgr;-interferons for the treatment of multiple sclerosis (MS) has created a dilemma for the UK National Health Service (NHS). There is now a therapy available for a disease where management has traditionally been limited to symptomatic treaments; however, it comes with a large price tag attached. At a time when rationing is becoming a reality in the NHS, how has the issue of interferon-&bgr; prescribing been handled and how are patients with MS faring? Delegates at a recent British Association of Pharmaceutical Physicians meeting*heard from representatives of 1 party involved in this debate - the pharmaceutical industry.
ISSN:1173-8324
出版商:ADIS
年代:1999
数据来源: ADIS
|
5. |
Levofloxacin cost saving in CAP |
|
Inpharma Weekly,
Volume &NA;,
Issue 1193,
1999,
Page 7-7
&NA;,
Preview
|
PDF (844KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1999
数据来源: ADIS
|
6. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 1193,
1999,
Page 8-8
&NA;,
Preview
|
PDF (811KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1999
数据来源: ADIS
|
7. |
The case for mitoxantrone in multiple sclerosis |
|
Inpharma Weekly,
Volume &NA;,
Issue 1193,
1999,
Page 9-10
Jo Dalton,
Preview
|
PDF (1738KB)
|
|
摘要:
Mitoxantrone [‘Novantrone’] is an antineoplastic agent that exerts potent immunomodulatory effects, including suppression of B cell immunity and reduction of T cell numbers. As a consequence, researchers have long since recognised mitoxantrone as a potential research candidate for autoimmune diseases such as multiple sclerosis (MS). A long-term, phase III, European trial demonstrating a mitoxantrone-associated delay in disease progression in patients with progressive MS has recently been highlighted.*These results were further elaborated upon and discussed at the 51st Annual Meeting of the American Academy of Neurology [Toronto, Canada; April 1999].
ISSN:1173-8324
出版商:ADIS
年代:1999
数据来源: ADIS
|
8. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 1193,
1999,
Page 11-11
&NA;,
Preview
|
PDF (766KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1999
数据来源: ADIS
|
9. |
Chronomodulated chemotherapy shows promise |
|
Inpharma Weekly,
Volume &NA;,
Issue 1193,
1999,
Page 12-12
&NA;,
Preview
|
PDF (804KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1999
数据来源: ADIS
|
10. |
Carboplatin casts cisplatin off the ovarian cancer stage |
|
Inpharma Weekly,
Volume &NA;,
Issue 1193,
1999,
Page 13-14
Carmen Innes,
Preview
|
PDF (1674KB)
|
|
摘要:
Cisplatin plus paclitaxel has been standard in the first-line treatment of ovarian cancer since the Gynecologic Oncology Group (GOG) 111 trial showed a significant improvement in survival in patients receiving this regimen, compared with cisplatin plus cyclophosphamide, in 1996.*Results from 2 similar large-scale trials in the US and Europe presented at the 35th Annual Meeting of the American Society of Clinical Oncology [Atlanta, US; May 1999] now indicate that carboplatin should replace cisplatin in the platinum/paclitaxel combination for standard treatment. Both trials showed equivalent efficacy and reduced toxicity with carboplatin, and that shortening the infusion time from 24 to 3 hours does not affect efficacy. Carboplatin is also more convenient to administer, with potentially reduced complication rates, reduced hospitalisation rates and reduced costs.
ISSN:1173-8324
出版商:ADIS
年代:1999
数据来源: ADIS
|